Bio-Path Holdings, Inc. BPTH

BPTH Company Overview

Bio-Path Holdings, Inc. is a U.S.-based clinical-stage biotechnology company focused on the development of RNAi nanoparticle therapeutics designed to target cancer and hematologic diseases. The company operates within the biotechnology and oncology drug development industries and concentrates primarily on antisense and RNA interference-based therapeutics delivered through proprietary drug delivery technologies. Bio-Path’s core value proposition centers on developing targeted treatments intended to improve efficacy and reduce toxicity relative to conventional chemotherapy approaches.

The company’s primary revenue model has historically depended on financing activities, licensing opportunities, and potential future commercialization of drug candidates, as Bio-Path has not yet generated material commercial product revenue based on publicly available filings. Its lead clinical assets include prexigebersen (formerly BP1001), liposomal Bcl-2-targeting therapies, and related pipeline candidates targeting acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), lymphoma, and solid tumors. Bio-Path was founded in 2007 and evolved from a development-stage biotechnology platform company into a clinical-stage oncology therapeutics developer through internal R&D efforts, clinical collaborations, and capital market financing.